Cybrexa Therapeutics reports that it has selected CBX-11 as its lead clinical development candidate for the treatment of patients with various solid tumors.

In addition, the company announced positive feedback from its pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA), concluding that the FDA agrees with the company’s proposed IND as well as the Phase 1 clinical development plans for CBX-11.